Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
| Revenue (Most Recent Fiscal Year) | $164.07M |
| Net Income (Most Recent Fiscal Year) | $-372.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.34 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.07 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -161.36% |
| Net Margin (Trailing 12 Months) | -161.44% |
| Return on Equity (Trailing 12 Months) | -52.87% |
| Return on Assets (Trailing 12 Months) | -41.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.73 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.33 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 361.85M |
| Free Float | 324.58M |
| Market Capitalization | $806.93M |
| Average Volume (Last 20 Days) | 14.25M |
| Beta (Past 60 Months) | 0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |